Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX)
Rhea-AI Filing Summary
Bank of America Corporation filed an amended Schedule 13G reporting beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock. This represents 4.0% of the class, based on 63,563,123 shares outstanding as of May 8, 2026, from MacroGenics’ May 13, 2026 Form 10-Q.
Bank of America reports no sole voting or dispositive power and shared voting and dispositive power over all 2,556,475 shares, held through wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and BofA Securities Europe SA. The filing confirms ownership of 5 percent or less of the class.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 2,556,475 shares
Percent of class: 4.0%
Shares outstanding baseline: 63,563,123 shares
+4 more
7 metrics
Beneficially owned shares
2,556,475 shares
MacroGenics common stock beneficially owned by Bank of America
Percent of class
4.0%
Portion of MacroGenics common stock class owned by Bank of America
Shares outstanding baseline
63,563,123 shares
MacroGenics shares outstanding as of May 8, 2026 from May 13, 2026 Form 10-Q
Sole voting power
0 shares
Shares over which Bank of America has sole voting power
Shared voting power
2,556,475 shares
Shares over which Bank of America has shared voting power
Sole dispositive power
0 shares
Shares over which Bank of America has sole dispositive power
Shared dispositive power
2,556,475 shares
Shares over which Bank of America has shared dispositive power
Key Terms
beneficial ownership, shared voting power, shared dispositive power, Schedule 13G, +1 more
5 terms
beneficial ownership financial
"The beneficial ownership calculation relies on the 63,563,123 outstanding shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Schedule 13G regulatory
"This statement on is being filed by Bank of America Corporation"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
parent holding company regulatory
"If a parent holding company has filed this schedule, pursuant to (ii)(G)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of MacroGenics (MGNX) does Bank of America report owning in this Schedule 13G/A?
Bank of America reports beneficial ownership of 4.0% of MacroGenics common stock. This is based on 2,556,475 shares owned versus 63,563,123 shares outstanding as of May 8, 2026, cited from MacroGenics’ May 13, 2026 Form 10-Q.
Which Bank of America subsidiaries hold the MacroGenics (MGNX) position reported on this Schedule 13G/A?
The statement is filed by Bank of America on behalf of itself and wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and BofA Securities Europe SA, each classified under applicable Exchange Act provisions.
Does Bank of America report owning more than 5% of MacroGenics (MGNX)?
No. Bank of America explicitly reports ownership of 5 percent or less of MacroGenics’ common stock. The filing states a 4.0% beneficial ownership based on 2,556,475 shares versus 63,563,123 outstanding shares.